NCT04475601

Enzalutamide Treatment in COVID-19

A Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Andreas Josefsson · Other Government
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

COVID-19 is a disease with high rate of morbidity if symptomatic. There is a great need of treatments to decrease the severity. The vast majority of patients needing intensive care are men, and this may be due to the androgens, either by regulation of TMPRSS2, necessary for virus internalization, or other mechanisms. Enzalutamide is an antiandrogen inhibiting the expression of androgen regulated proteins, such as TMPRSS2. The aim of this trial is to evaluate a possible beneficial effect of short-term enzalutamide treatment of COVID-19 patients.

Conditions

• COVID-19
• Corona Virus Infection

Interventions

Type	Name	Description
DRUG	Enzalutamide Pill	The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital

Timeline

• Start date: 2020-07-15
• Primary completion: 2021-03-24
• Completion: 2021-05-29
• First posted: 2020-07-17
• Last updated: 2022-06-02

Locations

6 sites across 1 country: Sweden